Abstract. Diabetic nephropathy is one of the leading hypothesis of abnormal matrix degradation in diabetic nephropathy has been addressed by experimental studcauses of renal failure in Western countries, where diabetic patients account for nearly half of all patients ies which demonstrated the inhibition of the degrading wing of matrix turnover; this possibly leads to deranged on haemodialysis. Progressive expansion of the mesangial matrix, and thickening of the glomerular and extracellular matrix ( ECM ) homeostasis, expansion of the mesangial matrix and glomerulosclerosis [5, 9] . tubular basement membranes without signs of major cell proliferation are hallmarks of human and experi-Human data in vivo are very similar to experimental findings, as the glomerular MMP2 gene is downmental diabetic nephropathy. These lesions eventually lead to glomerular fibrosis, a central pathological regulated in human diabetes. However, no relationship seems to exist between MMP2 gene expression and the feature in many human acute and chronic kidney diseases, which progressively destroys the renal filtra-severity of the renal diabetic disease. In fact, MMP2
( TGF-b) overexpression [12] . Whether these sequen-they might have a pathogenetic role. VEGF is an attractive candidate to function as a mediator of tial phenomena also occur in human diabetes is not known. While the temporal association between these endothelial dysfunctions in diabetes. Indeed, a number of similarities exist between diabetic retinopathy and molecular events and renal hypertrophy suggests that they play a pathogenetic role, this has been nephropathy, thus supporting a role for VEGF in both. The loss of smooth muscle-like cells (pericytes demonstrated unequivocally only for TGF-b [3] . Additionally, it is not clear whether these early events, in the retina, and mesangial cells in the glomerulus) has been reported both in retinopathy and in nephroincluding hypertrophy, drive the course of the disease towards diabetic glomerulosclerosis and renal failure. pathy [18, 19] . Furthermore, mesangiolysis in diabetic glomeruli seems to play a role in the formation of The later up-regulation of type IV collagen suggests a link between the very early up-regulation of growth microaneurysms [19] , whose presence in retinopathy is typical. Neoangiogenesis is also a common feature factors, and in particular TGF-b, and glomerular sclerosis [3] . However, it has not been proved that the of the two long-term complications of diabetes mellitus.
Indeed, blood vessel growth has been observed in the precocious activation of ECM protein genes invariably would be followed by diabetic nephropathy, which kidney in both the experimental streptozotocin model [20] and the human disease [21] . Increased vessel unfortunately is a very late and, at least in humans, variable event.
permeability, well known in the diabetic retina, might have its own counterpart in the microalbuminuria of Among growth factors, TGF-b has been the most studied in diabetic nephropathy. This is probably due diabetes, at least at the beginning. With this in mind, it is interesting to note that the same protein kinase C to the fact that the other growth factors do not have the 'right' actions, i.e. they are mitogenic and not (PKC ) b-isoform-selective inhibitor is capable of suppressing both the VEGF-induced retinal permeability particularly active in inducing a secretory phenotype in the glomerular and mesangial cells; on the contrary, [22] and early albuminuria in a rat diabetic model [23] .
How VEGF might play a role in the pathogenesis TGF-b exerts several activities, many of which explain quite well what is seen in diabetic nephropathy, in of diabetic nephropathy is still a matter of speculation.
Under physiological conditions, VEGF is produced in particular the accumulation of ECM by increasing the synthesis of ECM components and by reducing matrix the kidney by glomerular epithelial cells; mesangial and tubular epithelial cells apparently do not normally degradation. In fact, TGF-b1 gene overexpression in glomeruli from diabetic rats has been described in produce this growth factor, and it was suggested that VEGF expression by mesangial cells in vitro is related different experimental models as either very early or several weeks after diabetes onset [3, 13, 14] . TGF-b1 to hypoxic culture conditions [24] . However, vascular smooth muscle cells grown in high glucose medium mRNA is also increased in human diabetic glomeruli [14, 15] . Unlike other growth factors, i.e. PDGF, the recently were demonstrated to overexpress VEGF through PKC activation, thus raising the possibility TGF-b1 gene constantly is overexpressed at the renal level in different experimental models of diabetes and that similar cells, such as mesangial cells, might display a similar behaviour [25] . Interestingly, TGF-b, which in human diabetes. This selective up-regulation in the glomeruli suggests that this gene might be a target of is overexpressed in the diabetic kidney, also enhances VEGF expression [26 ] . Thus, there exist conditions in the metabolic events typical of the early phase of diabetic nephropathy. Since the promoter of the the diabetic kidney that potentially are capable of inducing VEGF overexpression. Hence, glomerular TGF-b1 gene contains the AP1 consensus sequence, Shankland et al. [16 ] suggested that the early increase permeabilization by VEGF might induce both albuminuria and an increased mesangial traffic of growth in c-fos and c-jun levels in glomerular cells is responsible for the subsequent rise in TGF-b1 mRNA levels in factors from the circulating blood. Growth factors might also originate from activated endothelial cells diabetic glomeruli.
due to the mitogenic activity of VEGF. Growth factors might then induce matrix synthesis by mesangial cells, leading to glomerulosclerosis. Although this patho-
VEGF and diabetic nephropathy
genetic scheme ( Figure 1 ) is purely speculative, it is supported by the observation of similar events in experimental models of vessel wall damage [27, 28] . It Vascular endothelial growth factor ( VEGF ) is a potent mitogen for vascular endothelial cells due to the pres-should be noted that this simple scheme does not consider other aspects of VEGF biology that might ence of specific receptors found only in these cells. VEGF is a major regulator of physiological angiogen-also have a special role in diabetic nephropathy, e.g. abnormal regulation in the alternative splicing of the esis, but it is also a crucial mediator of blood vessel growth associated with proliferative retinopathy [17] . VEGF gene, leading to the de novo appearance or disproportionate abundance in diabetes of some VEGF Its pathogenetic role in diabetic retinopathy seems to be overwhelming, and many experimental approaches molecular species, abnormalities in the expression/ function of VEGF receptors and abnormal matrix to limit its activity currently are being investigated to cure diabetic proliferative retinopathy. Endothelial binding of VEGF due to the altered sulfation of extracellular proteoglycans, a well-known phenomenon dysfunctions which are associated with diabetic nephropathy are well known, and it was suggested that in diabetes mellitus. To date, only two studies have
is the down-regulation of angiotensin II receptors in glomeruli and tubules of diabetic rats [32, 33] , which suggests a chronic, local overproduction of angiotensin II and a negative feedback that decreases receptor expression.
While clinical and experimental data support the existence of an unfavourable interaction between diabetes and RAS, the way in which this interaction occurs is not clear. Many observations demonstrate that angiotensin II-mediated signal transduction may be diminished rather than augmented, as expected, in the presence of high glucose [34, 35] . However, the finding that angiotensin II stimulates glucose uptake and the transcription of the glucose transporter GLUT-1 in a number of different cells [36, 37] raises the intriguing possibility that in diabetic patients at risk for diabetic nephropathy, a primitive increased RAS activity at the level of the kidney, due to a particular genetic background for instance, may lead to much higher intracellular concentrations of glucose compared to diabetics without diabetic nephropathy. The consequence of such a phenomenon is self-evident, as a number of cell abnormalities believed to lead to rather than the extracellular glucose concentrations.
Moreover, an additive mechanism between RAS and addressed the expression of VEGF in diabetic nephro-high glucose may be proposed; both apply similar or pathy patients [29, 30] ; the clinical characteristics of parallel signal transduction pathways in cultured renal the patients were not described, but most probably the cells. Activation of PKC in renal cells is typical of patients were in advanced stages of the disease. For diabetes and high glucose concentration [38] , and is this reason, considering the small number of subjects, important in the high glucose-mediated expression of no firm conclusion on the role of VEGF could be fibronectin, collagen IV and TGF-b in renal cells [31] . 
diabetic nephropathy
This has raised the hypothesis that an increased activity of the RAS and synthesis of angiotensin II might play a role in the initiation and progression of diabetic In vitro studies on cultured vascular smooth muscle, mesangial and proximal tubular cells have shown that nephropathy by non-haemodynamic mechanisms. Angiotensin II has many non-haemodynamic effects angiotensin II induces hypertrophic, fibrogenic and mitogenic responses reminiscent of those induced by on renal cells that may contribute to the progression of diabetic nephropathy. Angiotensin II may truly act growth factors, including TGF-b and PDGF. A body of evidence indicates that angiotensin II is a potent as a growth factor and a profibrogenic peptide, and it induces hypertrophy and/or proliferation of glomerular inducer of TGF-b, and that some of its reported effects are mediated directly by the expression of this growth and tubular cells, stimulates the synthesis of collagen and fibronectin, inhibits the synthesis of perlecan, and factor [41] . The induction of TGF-b by angiotensin II is also a PKC-dependent phenomenon [42], similar to lastly reduces ECM turnover [31] . However, although a consistent number of investigations have evaluated TGF-b induction by glucose. The available data have prompted the hypothesis that TGF-b constitutes the the systemic and renal expression of RAS components in diabetes, the effects of diabetes on the expression of missing link from glomerular hyperfiltration, i.e. a purely haemodynamic and RAS-dependent event, and each single component are still not fully understood.
glomerulosclerosis [41] . The recent demonstration that the search for ancillary therapy [4] [43] . RAS modulation seems warranted. By increasing the sensitivity of mesangial cells to TGFb, angiotensin II might be involved in the initiation of
Functional interplay between growth factors
the TGF-b autoinduction loop and, thus, might play an outstanding role in the derangement of the switch-
The interaction between angiotensin II and TGF-b is off mechanism which putatively is involved in the a clear example of the complexity and integration of healing process of renal lesions. Such a derangement the pathogenetic network causing diabetic glomerulowould promote lesion progression toward a chronic, sclerosis. Different pathogenetic levels may be recogfibrotic disease (glomerulosclerosis), rather than nized: metabolic irregularity; genetic susceptibility; remodelling to the original anatomo-functional struchaemodynamic components; the autocrine-paracrine ture [44] .
network, etc. Furthermore, each of these levels may The extension of the hypothesis that TGF-b is the be even more complex. Considering the autocrinemissing link between RAS and glomerulosclerosis, with paracrine network for example, a pivotal role in PKC occupying the convergence step between angiodiabetic nephropathy most likely can be ascribed to tensin II and high glucose-dependent pathways TGF-b, but perhaps also to VEGF. However, the to diabetic nephropathy, is a logical development levels of expression or activities of the single growth ( Figure 2 ). However, it is not known whether factors, and consequently the biological effects, intracellular high glucose and angiotensin II share the mutually interfere. In other words, we have to see the same intracellular signalling cascade (i.e. similar or autocrine-paracrine pathogenic level as an integrated different PKC isoforms) in TGF-b gene induction, network. No well-designed investigation has addressed although it was demonstrated in glomerular epithelial this problem in diabetes or in the 'high glucose' milieu cells that at least some effects are distinct, thus sugbut, in different experimental settings, it has been gesting different pathways [45] . Furthermore, there is demonstrated that the hypertrophic vs hyperplastic no perfect overlap between the biological effects of potential of angiotensin II depends on the level of angiotensin II and TGF-b on mesangial cells in vitro, TGF-b in proximal tubular cells [47] , and that the as clearly shown by differential effects on perlecan mitogenic activity of angiotensin II on smooth muscle production [46 ] . cells is partly dependent on the induction of PDGF The proposed model for the interaction between and TGF-b synthesis [48] . As a further example, high glucose, angiotensin II and TGF-b is, therefore, in experimental mesangio-proliferative glomerulosomewhat simplistic, but the relevance of its comprenephritis induced by anti-Thy 1.1 serum, glomerular hension is not merely speculative. It may offer the sclerosis is prevented by anti-TGF-b [49], anti-PDGF opportunity to discern additional pharmacological tar- [50] and anti-bFGF [51] antibodies, along with heparin gets for the treatment of diabetic nephropathy. As
[52]. Thus, it is possible to prevent sclerosis by acting clearly shown by the previous exceptions to the proon different sections of the same, complex pathogenetic posed model [45, 46 ] , full intervention in the different network. The recognized genetic background of diaevents triggered by high glucose, angiotensin II and betic nephropathy possibly also constitutes another TGF-b in diabetes mellitus most likely requires drugs level of this complex network. that act on different pathogenetic pathways. Therefore,
